Completed
Assessment of Physician Behavior Regarding Metabolic Monitoring of Patients Treated With SEROQUEL® (Quetiapine Fumarate) Tablets and SEROQUEL® (Quetiapine Fumarate) Extended Release Tablets in Selected Countries in the EU
What is being collected
Data Collection
Collected at a single point in time - Cross-sectionalWho is being recruted
Bipolar and Related Disorders+5
+ Mental Disorders
+ Depressive Disorder
+2 Eligibility Criteria
How is the trial designed
Observational
Study Start: June 2013
Summary
Principal SponsorAstraZeneca
Last updated: January 28, 2014
Sourced from a government-validated database.Claim as a partner
Study start date: June 1, 2013
Actual date on which the first participant was enrolled.Assessment of physician behavior regarding metabolic monitoring of patients treated with SEROQUEL® (quetiapine fumarate) Tablets and SEROQUEL® (quetiapine fumarate) Extended Release Tablets in selected countries in the EU
Principal SponsorAstraZeneca
Last updated: January 28, 2014
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
800 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Bipolar and Related DisordersMental DisordersDepressive DisorderMood DisordersSchizophrenia Spectrum and Other Psychotic DisordersBipolar DisorderDepressive Disorder, MajorSchizophrenia
Criteria
1 inclusion criteria required to participate
Physicians targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL or SEROQUEL XR
1 exclusion criteria prevent from participating
Physicians who have participated in a survey involving SEROQUEL / SEROQUEL XR in the past six months are not eligible to participate in this survey
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
8 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers